GEGhada Nabil Elnaggar

Ghada Nabil Elnaggar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ghada Nabil Elnaggar has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Abeer Ismail

    Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt

    2 shared publications
  • Abbas Mohamed

    Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt

    1 shared publication
  • Ahmad Samir Elshazly

    Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt

    1 shared publication
  • Dina M. Elkhashab

    Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt

    1 shared publication
  • Lamiaa Ali Bayoumi

    Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt

    1 shared publication
  • Maha Yahia

    Department of Medical Oncology, National Cancer Institute, Cairo University, Egypt

    1 shared publication

Latest Publications

  • Open Access

    Role of miR-15b and miR-130b as Non-Invasive Biomarkers in Hepatocellular Carcinoma

    by Noha H Ibrahim, Ahmad Samir Elshazly, Mohamed Ghareeb, Dina M. Elkhashab, Ghada Nabil Elnaggar

    Background: Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers, and the second cause of cancer-related deaths worldwide. MicroRNAs play a role in regulating gene expression transcriptionally and post-transcriptionally. Accordingly, they can affect cancer risk. This study aimed to highlight the diagnostic role of miR-15b and miR-130b as non-invasive biomarkers in Egyptian HCC patients. Materials and Methods: This study included 70 patients with confirmed HCC, 35 cirrhotic patients with chronic hepatitis B or C virus infection, and 35 apparently healthy persons. Plasma miR-15b and miR-130b levels were measured by TaqMan RT-PCR assay. Results: Significant higher expression levels of plasma miR-15b and miR-130b were observed in HCC patients compared to hepatitis group or control group or the non-malignant group (P <0.0001 each). Combining miR-15b with AFP markedly raised the sensitivity to 91.4%, while combination of miR-130b with AFP significantly improved the specificity to 97.1 %. Combining the three markers showed excellent discriminatory power with AUC 0.959 and overall diagnostic accuracy 92.6% for differentiation between HCC from the non-malignant cases. Conclusion: MiR-15b and miR-130b could serve as possible biomarkers for HCC detection, and combining these markers with AFP could markedly improve the diagnostic accuracy for HCC.


  • Open Access

    Possible Role of IL-6R/STAT3/MiRNA-34a Feedback Loop in Osteosarcoma

    by Marwa Fathy Amer, Abbas Mohamed, Abeer Ismail, Lamiaa Ali Bayoumi, Passant Essam Eldin Shibel, Ghada Nabil Elnaggar

    Objective: Osteosarcoma is considered the most common primary malignant tumor that develops from the primary osteoblasts. MiRNAs are small non-coding RNAs that play a key role in tumorigenesis. The aim of this study was to detect the possible relationship between expression levels of miRNA-34a and levels of Signal transducer and activator of transcription 3 (STAT3) and interleukin-6 receptor (IL-6R) in osteosarcoma and the possible role of this relationship in development of metastases in these patients. Methods: A total of thirty-six (36) bone samples were included in the study. They were divided into 3 groups: Group (I): Twelve normal bone samples as control group. Group (II): Twelve patients with non-metastatic osteosarcoma. Group (III): Twelve patients with metastatic osteosarcoma. MiRNA-34a expression levels were estimated using qRT-PCR. STAT3 and IL-6R levels were measured by ELISA. Results: Expression level of miRNA-34a was downregulated in osteosarcoma groups compared to control group. STAT3 and IL-6R levels were upregulated in osteosarcoma groups compared to control group. This difference in expression levels was found to be more significant in the metastatic group than the non-metastatic one (P<0.001 each). There was a significant positive correlation between STAT3 and IL-6R (r=0.868, P<0.001), and a significant inverse correlation between IL6 and miRNA-34a (r=-0.993, P<0.001). Conclusion: miRNA-34a, STAT3 and IL-6R feedback loop could be a potential target for treatment of osteosarcoma and can be used as prognostic indicator for this disease.


  • Open Access

    Micro RNA-148a Targets Bcl-2 in Patients with Non-Small Cell Lung Cancer

    by Ghada Nabil Elnaggar, Niveen M El-Hifnawi, Abeer Ismail, Maha Yahia, Reham Elshimy

    Objective: Lung cancer is one of the most prevalent cancers and the leading cause of cancer-related deaths worldwide. MicroRNAs regulate more than 60% of human genes, including tumor suppressor genes and oncogenes. Accordingly, they can affect cancer risk. This study aimed to evaluate the role of serum miR-148a as a non-invasive biomarker in non-small cell lung cancer (NSCLC) patients and to assess the correlation between miR-148a and Bcl-2, as one of its target proteins. Materials and Methods: A total of 50 newly diagnosed NSCLC cases and 30 apparently healthy controls were recruited in this study. MiR-148a level was measured by TaqMan- Real time RT-PCR assay and Bcl-2 level was measured by ELISA. Results: Significant lower expression of serum miR-148a and higher serum Bcl-2 levels were observed in NSCLC patients as compared to the control group (p